Immediate Delivery Versus Expectant Monitoring for Hypertensive Disorders of Pregnancy Between 34 and 37 Weeks of Gestation (HYPITAT-II): An Open-Label, Randomised Controlled Trial

Kim Broekhuijsen*, Gert-Jan van Baaren, Maria G. van Pampus, Wessel Ganzevoort, J. Marko Sikkema, Mallory D. Woiski, Martijn A. Oudijk, Kitty W. M. Bloemenkamp, Hubertina C. J. Scheepers, Henk A. Bremer, Robbert J. P. Rijnders, Aren J. van Loon, Denise A. M. Perquin, Jan M. J. Sporken, Dimitri N. M. Papatsonis, Marloes E. van Huizen, Corla B. Vredevoogd, Jozien T. J. Brons, Mesrure Kaplan, Anton H. van KaamHenk Groen, Martina M. Porath, Paul P. van den Berg, Ben W. J. Mol, Maureen T. M. Franssen, Josje Langenveld, HYPITAT-II Study Grp

*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

Fingerprint

Dive into the research topics of 'Immediate Delivery Versus Expectant Monitoring for Hypertensive Disorders of Pregnancy Between 34 and 37 Weeks of Gestation (HYPITAT-II): An Open-Label, Randomised Controlled Trial'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science